Here is why Mizuho analyst upgraded to buy ratings from neutral

Demand for pharma products through retail channels and command of logistic channels are some of the key reasons behind Mizuho analyst James Lee's upgrade of While its upcoming Hong Kong listing doesn't change the financial fundamentals for the company, James says it provides a good source of liquidity from Asian markets for the company.
Fri, May 15 20201:37 AM EST